An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 230 participants.

Also called NCT01638507

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 230 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01638507
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01638507. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-11-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
Acronym
RI-US
Intervention (Device)
Resolute Integrity Stent
Lead sponsor
Medtronic Vascular (class: industry)

Record details

Record id
cardio:ct-nct01638507
Content hash
fe3a84ed3ab086a042bbab924fc6056fd351a3ae5a53c7a318cb166ee78c4a00